Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

Blood Cancer J. 2014 Aug 29;4(8):e242. doi: 10.1038/bcj.2014.62.

¹ Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
² Celgene Corporation, Summit, NJ, USA.
³ Service d'Hématologie Séniors, Hôpital St Louis, Université Paris 7, Paris, France.
⁴ Stanford University Cancer Center, Stanford, CA, USA.
⁵ Hospital Universitario y Politécnico La Fe, Valencia, Spain.
⁶ University of Rochester Medical Center, Rochester, NY, USA.
⁷ Hôpital Cochin, Université Paris, Paris, France.
⁸ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

No abstract available

Publication types